Evidence map›Paper›PMID 38541111›Full record

ReviewMedicina (Kaunas, Lithuania)2024

Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review.

Poramate Pitak-Arnnop, Popchai Ngamskulrungroj, Nithi Mahanonda, Prim Auychai, Benjamin Frech, Veronika Shavlokhova, Christian Stoll

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 2 countries.

Poramate Pitak-ArnnopDepartment of Oral and Craniomaxillofacial Plastic Surgery, UKGM University Hospital Marburg, Faculty of Medicine, Philipps-University Marburg, D-35043 Marburg, Germany.ORCID 0000-0002-7427-3461
Popchai NgamskulrungrojDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Nithi MahanondaChulabhorn Royal Academy, Bangkok 10210, Thailand.
Prim AuychaiThai Association of Pediatric Dentistry, Bangkok 10400, Thailand.
Benjamin FrechDepartment of Oral, Craniomaxillofacial and Plastic Surgery, University Hospital Ruppin-Brandenburg, Faculty of Medicine, Medical University Brandenburg, D-16816 Neuruppin, Germany.
Veronika ShavlokhovaDepartment of Oral, Craniomaxillofacial and Plastic Surgery, University Hospital Ruppin-Brandenburg, Faculty of Medicine, Medical University Brandenburg, D-16816 Neuruppin, Germany.
Christian StollDepartment of Oral, Craniomaxillofacial and Plastic Surgery, University Hospital Ruppin-Brandenburg, Faculty of Medicine, Medical University Brandenburg, D-16816 Neuruppin, Germany.
Beiersdorf (Germany) · DEChulabhorn Hospital · THMedizinische Hochschule Brandenburg Theodor Fontane · DEPhilipps University of Marburg · DESiriraj Hospital · THThe Royal College Of Anesthesiologists Of Thailand · THUniversitätsmedizin Greifswald · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the World Health Organization (WHO) has de-escalated coronavirus disease 2019 (COVID-19) from a global health emergency, ongoing discussions persist as new viral variants. This article aimed to consolidate German recommendations and international research to offer health care providers (HCPs) a comprehensive guide on COVID-19 boosters in 2024. The review outlines key recommendations from the German Robert Koch Institute. HCPs should receive COVID-19 boosters at least 12 months after their last vaccination or COVID-19 infection, contingent on the prevalent viral variant(s) in the region. However, excessive doses and/or frequent boosters, especially with mRNA vaccines, may lead to immune imprinting, T-cell exhaustion, and immunoglobulin (Ig) switching. Notably, this review highlights the significance of Ig, particularly IgA and IgG subclasses, in influencing infection risk and disease progression. Furthermore, it explores the implications of mRNA vaccine technology and potential adverse effects related to excessive dosing. In conclusion, this article provides a comprehensive analysis of COVID-19 vaccine boosters for HCPs, synthesising current recommendations, scientific debates, and considerations for optimising protection against SARS-CoV-2 in the evolving landscape of the post-pandemic era.

Indexed as

COVID-19Antibodies, ViralCOVID-19 VaccinesHealth PersonnelHumansmRNA VaccinesSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesmRNA VaccinesCOVID-19health care providerreviewvaccine booster

Identifiers

PMID38541111
PMCPMC10971846
OpenAlexW4392155569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.